Cardiovascular disease remains the leading cause of death in renal transplant recipients, but the underlying causative mechanisms for this important problem remain elusive. Recent work has indicated that qualitative alterations of HDL affect its functional and compositional properties in ESRD. Here, we systematically analyzed HDL from stable renal transplant recipients, according to graft function, and from patients with ESRD to determine whether structural and functional properties of HDL remain dysfunctional after renal transplantation. Cholesterol acceptor capacity and antioxidative activity, representing two key cardioprotective mechanisms of HDL, were profoundly suppressed in kidney transplant recipients independent of graft function and were comparable with levels in patients with ESRD. Using a mass spectroscopy approach, we identified specific remodeling of transplant HDL with highly enriched proteins, including a-1 microglobulin/bikunin precursor, pigment epithelium-derived factor, surfactant protein B, and serum amyloid A. In conclusion, this study demonstrates that HDL from kidney recipients is uniquely altered at the molecular and functional levels, indicating a direct pathologic role of HDL that could contribute to the substantial cardiovascular risk in the transplant population.
Kidney transplantation (KTx) is the preferred therapy for the majority of patients with ESRD because overall survival and quality of life are better than with hemodialysis. 1, 2 Despite this, transplant recipients have an up to 10-fold higher cardiac risk compared with the general population and this remains the largest single cause of death with a functioning graft. 3 Accordingly, reducing cardiovascular mortality remains a major goal in post-transplant medical care. Conventional risk factors such as hypertension, diabetes, renal dysfunction, and anemia are highly prevalent in transplant patients 4 but there is currently no convincing evidence that specific therapeutic interventions are effective. 3, 5 This suggests that distinct pathogenetic mechanisms or combinations of mechanisms possibly owing to a complex interplay of acquired cardiovascular risk factors, decreased kidney function, and immunosuppressants are responsible. The excess cardiovascular risk in this population might also be considerably influenced by other factors such as structural and functional alterations in lipoprotein metabolism.
Dyslipidemia is a significant risk factor for the development of coronary artery disease in the general population and is common after organ transplantation, although its exact role in post-transplant cardiovascular disease (CVD) has not been defined. Lipid metabolism remains abnormal despite recovery of renal function after transplantation and may be associated with reduced graft and patient survival. 4, 6, 7 Large prospective trials have shown that treatment with statins does not significantly reduce cardiac death and overall mortality in patients with advanced CKD, nor does it improve graft survival of kidney transplants. [8] [9] [10] [11] [12] This indicates an atypical pathophysiology underlying cardiovascular events in patients with CKD, particularly after kidney transplantation, 13 pointing toward specific and so far unidentified cardiovascular risk factors. HDL has evolved as one of the most promising candidates in the setting of dyslipidemia in patients with CKD. 14, 15 The association between plasma HDL cholesterol and cardiovascular events remains inconsistent and recent studies have shown that qualitative parameters of HDL, rather than mere quantity, are essential for its atheroprotective properties. [16] [17] [18] Importantly, the cholesterol acceptor capacity of HDL correlates inversely with CVD status, independent of HDL concentrations. 19 Hence, it is assumed that the cardioprotective effects of HDL are largely based on its ability to remove cholesterol from macrophages, which represents the first and crucial step of reverse cholesterol transport. 20 In recent years, it has become evident that the atheroprotective, anti-inflammatory, and antioxidative effects of HDL are critically dependent on its protein cargo [21] [22] [23] [24] because HDLassociated proteins were found to be involved in many biologic functions apart from lipid metabolism, such as regulation of inflammation and immune responsiveness. 15 We and others have shown that qualitative alterations of HDL in CKD and ESRD result in dysfunctional properties, transforming HDL from a protective to a deleterious particle. 16, 17, 25, 26 The concept of merely increasing HDL levels by pharmacologic interventions, however, is proven to be ineffective 27 and novel innovative strategies to improve HDL functions could be promising for patients with impaired renal function.
Here, we investigated whether the defective function and altered composition of uremic HDL are restored after renal transplantation. This explorative study was designed to characterize the functional properties and molecular phenotype of HDL obtained from stable renal transplant patients with good or poor renal function.
RESULTS

Clinical Characteristics of Study Participants
The clinical and general characteristics of all study participants are given in Tables 1 and 2 Paraoxonase Activity of HDL from Transplant Patients Is Reduced A key antiatherogenic feature of HDL is represented by its antioxidative activity conferring protection of LDL from oxidation. 28 We analyzed the influence of kidney transplantation on the enzymatic efficiency of the major HDL-associated antioxidative enzyme paraoxonase (PON) by measuring its arylesterase activity. We found that PON efficacy of HDL was significantly reduced in both transplant groups to a similar extent. ESRD HDL displayed further decreased PON activity compared with controls ( Figure 1 ). Transplant HDL Displays Impaired Cholesterol Homeostasis Cholesterol efflux from macrophages to HDL represents the first step in reverse cholesterol transport, indicative of its atheroprotective activity. 29 We observed that the capacity of KTx poor and ESRD HDL to accept cholesterol from lipid-laden macrophages was reduced by 14% and 12%, respectively. Notably, HDL from KTx good patients showed a significantly reduced cholesterol efflux rate by 21.5% (Figure 2A ). In addition, we found substantial free cholesterol accumulation in leukocytes from transplant and ESRD patients ( Figure 2B ). Correlation analysis of efflux capability with cholesterol accumulation revealed a significant negative association between these parameters ( Figure 2C ). For a more detailed characterization of the proteomic profile, relative protein abundance among the individual groups was calculated by a peptide index to determine differences in protein quantity as previously described. 16, 18 We found 40 proteins, which were enriched in at least two of the patient groups compared with controls ( Figure 4 ). Focusing on proteins absent in HDL of controls (Supplemental Table 1 ) and in line with previous results from patients with ESRD, 16 we found the protease inhibitors a-1 microglobulin/bikunin precursor (AMBP) and pigment epithelium-derived factor (PEDF), the acute phase protein serum amyloid A (SAA), and lipid metabolism-associated surfactant protein B (SP-B) accumulated in ESRD HDL and, surprisingly, in both KTx good and KTx poor patients. Comparing the transplant groups, SAA, AMBP, and PEDF were increased in HDL of KTx poor patients compared with KTx good HDL (Supplemental Figure  1A ). Assessing differences between transplant and ESRD HDL, we found SP-B to be enhanced in ESRD HDL compared with both KTx groups (Supplemental Figure 1 , B and C). Generally, HDL from patients with ESRD displayed profound enrichment of the immune-related proteins AMBP, SAA, and PEDF compared with KTx good HDL, whereas these proteins were found in higher levels in KTx poor compared with patients with ESRD, indicating that renal function may be related to alterations of the protein cargo on HDL. 16 ESRD HDL showed high expression of AMBP, SAA, SP-B, and PEDF ( Figure 5 ) and the same HDL-bound proteins were detectable at similarly increased levels in KTx poor HDL. Remarkably, these specific uremia-related proteins were also enriched in KTx good HDL to an equal degree as in KTx poor HDL. These results were extended to a specific HDL-ELISA (described in the Concise Methods). As depicted in Figure 6 , detection of HDL-bound SP-B and SAA showed a significant increase of both proteins in transplant recipients and patients with ESRD, indicating that specific proteins are selectively expressed in HDL of uremic patients.
DISCUSSION
The underlying mechanisms for the high cardiovascular risk after renal transplantation remain largely unknown. It is now well established that the molecular composition of HDL strongly correlates with its functions and that its atheroprotective properties are severely impaired in different disease settings, including chronic renal insufficiency. [30] [31] [32] We investigated whether HDL remains dysfunctional after renal transplantation, because systematic and detailed characterization of HDL from transplant recipients could provide critical information regarding possible causes for their high cardiovascular risk. Proteomic analysis identified a highly heterogeneous protein cargo among uremic HDL, which differs in the transplant population itself, demonstrated by the opposing distribution of proteins according to biologic functions between KTx good and KTx poor HDL. Although the HDL proteome of KTx good patients seems to recover toward a healthy phenotype, specific proteins such as AMBP, PEDF, SAA, and SP-B nevertheless remain to be highly enriched comparable to KTx poor and ESRD HDL.
Of note, KTx poor HDL displays a distinct distribution pattern with the most profound decrease of lipid metabolism proteins and concordant increase of immune and transport-related proteins compared with all other groups. This specific HDL profile could result from a combination of the underlying systemic inflammatory state, decline of kidney function after transplantation, and/or advanced uremia. We previously demonstrated 16 that the Figure 1 . Paraoxonase activity of HDL is impaired after kidney transplantation. Arylesterase activity of HDL-associated paraoxonase is measured using phenylacetate as the substrate. HDL from healthy controls as well as KTx good , KTx poor , and ESRD patients (n=17 per group, except n=18 for KTx good ) is used at a concentration of 20 mg/ml. The results show the means6SEM of two individual experiments performed in duplicates. Statistical analysis is performed by the two-tailed t test. *P,0.05; ***P,0.001. aforementioned candidate proteins are hardly detectable in HDL of stage 3 CKD and gradually start to accumulate in patients with stage 4 CKD, arguing for specific transplantand/or dialysis-related factors that may account for this selective protein enrichment. It was previously suggested that the frequency of cardiovascular complications after transplantation is correlated with time spent on dialysis. 33 Because all of our participants were patients with previous ESRD and most experienced hemodialysis before renal transplantation, it may be possible that ESRD per se may imprint specific changes reflected by a unique protein cargo of HDL. Of note, two proteins that were found enriched in ESRD HDL and remained highly expressed on transplant HDL were SAA and SP-B. These candidates could emerge as potential novel markers to predict cardiovascular outcome after renal transplantation. SAA has consistently been found in HDL from individuals with diseases bearing major cardiovascular risks. 21 We previously showed that enrichment of SAA in HDL of patients with ESRD was related to defective anti-inflammatory functions, which could be confirmed by other studies. 16, 17, 34 This indicates that the accumulation of SAA on uremic HDL may contribute to disease progression and subsequently enhances their cardiovascular risk by contributing to the patient's inflammatory state. Furthermore, SP-B was found to be highly enriched in HDL of patients with coronary artery disease and patients with ESRD. 16, 30 High circulating SP-B levels were recently shown to be associated with aortic atherosclerosis in smokers 35 and plasma SP-B could be identified as a biomarker for chronic heart failure, 36 indicating an association of elevated SP-B levels with CVD. It can be additionally hypothesized that increased postcapillary hypertension found in many hemodialysis patients 37 may lead to selective enrichment of SP-B on HDL, a condition that is possibly difficult to influence after transplantation. Further studies are underway to address the issue of whether the amounts of HDL-bound SAA and SP-B could serve as accurate markers for clinical events or cardiovascular outcomes in high-risk populations.
To date, our understanding of the proteomic diversity of HDL has made major advances and has been found to be highly characteristic in several diseases with high cardiovascular risk. 24, 31, 32, 38 These associations indicate that HDL remodeling might not only contribute to disease characteristics but might also play a crucial role in disease progression. 39 Our data revealed that although a general recovery of protein distribution seems to occur in transplant patients with functioning grafts, individual proteins remain to be enriched, signifying a unique molecular composition of uremic HDL after transplantation. Recent studies have shown an association of HDL-cholesterol levels as predictors of CKD progression, but not with CVD risk. [40] [41] [42] This is in line with our findings that KTx good patients have higher HDL-cholesterol levels compared with KTx poor patients (Table 1) , which is likely a consequence of recovered renal function. A major finding of our study is that functional properties of HDL remain compromised after renal transplantation, shown by substantial impairments in both KTx groups similar to patients with ESRD. Importantly, HDL dysfunctions were independent of graft function, because there were no differences between the KTx patients, even after reclassification of the transplant groups according to different cut-off values for defining good and poor graft function (Supplemental Figure 2 , Supplemental Table 2 ). These results clearly differ from the conventional CKD population, where we could not observe considerable functional impairments of HDL in stage 4 CKD, although these findings were restricted to cholesterol efflux measurements (C. Kopecky, unpublished data). Thus, studying HDL quality prospectively should provide important information on critical influencing factors in this setting. During the course of our study, four patients, who were receiving hemodialysis at the time of recruitment, received a kidney transplant. We assessed functional and structural HDL parameters of these patients and compared them with participants remaining on hemodialysis. Clinical characteristics of the prospectively followed hemodialysis patients are shown in Supplemental Table 3 . In agreement with our original data, no improvements in antioxidative activity or cholesterol efflux capacity were found in HDL of previous hemodialysis, meanwhile transplanted patients (Supplemental Figure 3) . Furthermore, the HDL proteome showed the same expression pattern with enrichment of specific proteins in the transplant group (Supplemental Figure 4) . Further studies are underway to explore the sequential relationship of transplant-specific changes in HDL quality. A possible transplant-related factor could be the influence of immunosuppression on lipoprotein composition. All transplant patients in this study were receiving a calcineurin inhibitor-based regimen with approximately two-thirds taking tacrolimus versus cyclosporine. We have not observed any differences in baseline clinical parameters or dysfunctional properties of HDL between these two groups (Supplemental Figure 5 , Supplemental Table 4 ). However, because our sample size was relatively small within the transplant groups, additional analyses with adequate sample sizes are necessary to address this specific issue. Furthermore, it will be highly interesting to determine the relative importance of other immunosuppressants, including mammalian target of rapamycin inhibitors and cytotoxic T-lymphocyte antigen-4-Ig, on HDL properties.
The atheroprotective quality of HDL results from the aggregated effects of its functional properties, which are known to be drastically altered in the course of many systemic diseases. 15, 43, 44 In this context, it is critical to identify underlying mechanisms contributing to the persistent cardiovascular risk after renal transplantation considering that HDL is a multifaceted modulator in many biologic processes related to CVD. Potent antioxidative properties of HDL are of major importance in CVD prevention, given the effect of oxidative stress in the development and progression of atherosclerosis. 45 The activity of the cardinal antioxidative HDL protein, paraoxonase, was considerably diminished in ESRD and transplant patients corresponding with decreased concentrations at the proteomic level in transplant HDL. Interestingly, recent studies showed a reduced antioxidative capacity of HDL in coronary artery disease and acute coronary syndrome. 31, 46, 47 The ability of HDL to remove excess cholesterol from the periphery critically reflects its antiatherogenic potency and is considered essential in the prevention of atherosclerotic plaque formation. 48, 49 Here, we showed highly impaired cholesterol acceptor capacity of transplant and ESRD HDL, as previously demonstrated by several groups 17, 25 along with a significant enrichment of free cholesterol in leukocytes of transplant and ESRD patients. Importantly, augmentation of cellular cholesterol further substantiates a defective overall reverse cholesterol transport function, which may contribute to the excessive cardiovascular risk in the CKD population. 49 In recent years, the so-called "HDL-flux hypothesis" has been emphasized to replace the traditional "HDL-cholesterol hypothesis." This takes account of the current consensus that HDL-cholesterol concentrations do not efficiently reflect HDL functions in vivo, and emphasizes the need for novel functional assays that are more accurate in estimating the atheroprotective potential of HDL. [19] [20] [21] 50 Overall, evaluation of HDLcholesterol efflux provides a dynamic measure of reverse cholesterol transport effectiveness and offers accurate information for assessing the efficacy of potential HDLtargeted therapies. 51 In conclusion, we have demonstrated that HDL from renal transplant recipients has a markedly altered molecular composition together with impairment of key HDL functions. These alterations may substantially contribute to the defective atheroprotective qualities of HDL and thus could constitute one of the underlying reasons for the high cardiovascular morbidity and mortality in the transplant population. Moreover, chronic renal failure after transplantation has a strong effect on structural and functional features of HDL and is different from conventional CKD. Our data provide a rational background for studying distinct HDLbound proteins that are specifically enriched in certain diseases with excessive cardiovascular risk as novel biomarkers and indicate that the assessment of defined functional properties of HDL can serve as a measure and predictor of the cardiovascular burden after kidney transplantation.
CONCISE METHODS
Study Population
This study was approved by the local ethics committee of the Medical University of Vienna according to the Declaration of Helsinki (EK 589, EK 1038). Informed consent was obtained from all participants. A total of 36 renal transplant recipients were included and grouped according to stringent clinical criteria into a group of 18 patients with good graft function (defined by an eGFR of .40 ml/min per 1.73 m 2 and serum creatinine of ,1.5 mg/dl) and a group of 18 patients with poor graft function (defined by an eGFR of ,30 ml/min per 1.73 m 2 and serum creatinine of . 3.5 mg/dl). eGFR was calculated according to the MDRD equation. 52 None of the patients were highly sensitized at the time of transplantation. At the time of study inclusion, none of the patients showed indication of allograft rejection and only one patient in the group with good graft function was identified to have low levels of donor- Figure 6 . Detection of HDL-bound SP-B and SAA from apoB-depleted serum. Levels of SP-B(HDL) (A) and SAA(HDL) (B) from apoB-depleted serum are measured by a novel assay developed by our laboratory. HDL from apoB-depleted serum samples of the indicated groups is bound to ELISA plates with a specific HDL-catching antibody; detection of proteins is performed using accordant primary antibodies and appropriate secondary antibodies and protein levels are assessed by measuring absorbance at 450 nm. Values (n=14 per group) represent the means of two measurements performed in triplicates; lines represent the means of each group. Statistical significance is calculated by the Mann-Whitney U test. *P,0.05; **P,0.01; ***P,0.001. specific antibodies. All transplant patients were receiving a calcineurin inhibitor-based immunosuppressive regimen (most commonly tacrolimus) combined with low-dose corticosteroids and mycophenolic acid as an antimetabolite (see Table 2 ). Eighteen patients with ESRD undergoing maintenance hemodialysis for a minimum of 3 months and 18 healthy controls with normal kidney function were recruited as comparative groups. Participants were in a stable condition and were free of recurrent illness (no infectious disease in the last 3 months, no signs of active cytomegalovirus infection, no acute cardiac events in the last 6 months, no metabolic or malignant disease). Venous fasting blood samples were obtained from transplant patients during routine clinic visits, and samples from patients with ESRD were taken at the beginning of the dialysis session. Blood was immediately placed on ice and centrifuged at 5003g for 15 minutes at 4°C to obtain plasma or serum. ApoBdepleted serum was prepared by the addition of 20% polyethyleneglycol (Sigma-Aldrich, St. Louis, MO) to precipitate apoB-containing lipoproteins from serum according to a protocol described by Asztalos et al. 53 
Isolation of HDL
HDL was isolated from plasma by a one-step density gradient ultracentrifugation as previously described. 17 In brief, the density (d) of plasma was raised to d=1.24 g/ml by the addition of potassium bromide (Sigma-Aldrich). The density gradient was generated by layering the density-adjusted plasma underneath a PBS solution (d=1.06 g/ml). The samples were then centrifuged in a type 75 Ti rotor in an Optima L-80 ultracentrifuge (Beckman Coulter, Fullerton, CA) at 60,000 rpm for 5 hours at 15°C. After collecting the HDL fraction, samples were desalted by filtration on PD-10 polyacrylamide columns (Thermo Fisher Scientific, Waltham, MA) and stored at 280°C.
Arylesterase Activity Assay
Paraoxonase-associated arylesterase activity was measured with a photometric assay using phenylacetate as the substrate. HDL (25 mg/ml) was added to a reaction buffer (100 mM Tris, 2 mM CaCl 2 pH 8.0, 1 mM phenylacetate). The rate of hydrolysis of phenylacetate was determined by monitoring the increase of absorbance at 270 nm on a microplate reader (XMark; Bio-Rad, Hercules, CA). The slope from the kinetic chart was used to determine DAbs 270nm /min. Enzymatic activity was calculated with the Beer-Lambert law from the molar extinction coefficient of 1310 L/mol per centimeter for phenylacetate and was expressed as millimoles per liter per minute per milligram of HDL protein.
Cellular Cholesterol Efflux Assay
Human THP-1 macrophages, derived from a human monocyte cell line, were plated on 48-well dishes, grown overnight, and labeled for 24 hours with [ 3 H]-cholesterol (1 mCi/ml) in RPMI 1640 with 10%
FBS. After labeling, cells were equilibrated in serum-free medium for 2 hours, rinsed, and incubated with 50 mg/ml HDL for an additional 3 hours at 37°C. For determination of cellular cholesterol efflux to HDL, [ 3 H]-cholesterol content was measured by liquid scintillation counting after separate collection of supernatants and cell lysates (Hidex 300SL; Hidex, Turku, Finland). Cholesterol efflux to HDL is expressed as radioactivity in the medium relative to total radioactivity in medium and cell lysates.
Cellular Cholesterol Quantification
Leukocytes from participants were isolated as previously described. 16 The 
Shotgun Proteomics
Fourteen randomly selected HDL samples from each patient group and 15 controls were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). For tryptic digestion, 50 mg of HDL preparations were precipitated with 3 volumes of acetone at 220°C overnight, solubilized in 30 ml 6 M urea, reduced with 5 mM dithiothreitol for 20 minutes by shaking at 550 rpm at 56°C, and alkylated with 20 mM iodoacetamide by shaking at 550 rpm at room temperature for 15 minutes. After dilution in 50 mM ammonium bicarbonate and 0.75 M urea, protein was digested by adding 1 mg of Promega modified trypsin and shaking overnight at 550 rpm at 37°C. The resulting peptide solution was acidified by adding 3.6 ml of 5% formic acid and was diluted in solvent A to a theoretical final concentration of 50 ng/ml. Forty microliters was separated by nano-HPLC on an Agilent 1200 system equipped with a Zorbax 300SB-C18, 5 mm, 530.3 mm enrichment column and a Zorbax 300SB-C18, 3.5 mm, 15030.075 mm nanocolumn. Forty-microliter samples were injected and concentrated on the enrichment column for 6 minutes using 0.1% formic acid as the isocratic solvent at a flow rate of 20 ml/min. Switching the column into the nanoflow circuit, the sample was loaded for 6 minutes on the nanocolumn (flow rate 300 nl/min) and separated using the following gradient: solvent A: water, 0. 
LC-MS/MS Data Analyses
The LC-MS/MS data were analyzed by searching the human SwissProt public database with Proteome Discoverer 1.3 (Agilent Technologies) and Mascot 2.3 (MatrixScience). Detailed settings are as follows: enzyme: trypsin, maximally missed cleavage sides: 2; N terminus: hydrogen, C terminus: free acid; search mode: homology search, possible multiple oxidized methionine and carbamylated lysine, maximum precursor charge 3, precursor mass tolerance610 ppm, product mass tolerance60.7 Da; acceptance parameters were one or more identified rank 1 peptides only in top-scored proteins after automatic validation (Mascot significance threshold P,0.05, Mascot ion score .17, false discovery rate,5%).
Spectral counts (the number of MS/MS spectra assigned to a protein) of identified proteins were subjected to statistical analysis by SPSS 18.0 software (SPSS Inc., Chicago, IL). Only proteins with a mean spectral count of $4 in either group were accepted. 54 The SD of spectral counts was ,10% between duplicates. The Mann-Whitney U test was utilized for analysis of differences between the two groups (P,0.05). For each protein, peptide indices were calculated to account for spectral counts equal to zero using the following equation: [(peptides in group 1/total peptides)3(total number of participants/ number of participants in group 1)3(% of participants in group 1 with $1 peptide)]2[(peptides in group 2/total peptides)3(total number of participants/number of participants in group 2)3(% of participants in group 2 with $1 peptide)]. 18 
Immunoblotting and ELISA Analyses
Identification of individual HDL-associated proteins was confirmed by Western blot analysis. Ten micrograms of HDL were separated by SDS-PAGE, transferred onto a polyvinylidene fluoride membrane, and probed overnight at 4°C with primary antibodies for AMBP, SAA, and SP-B (Santa Cruz Biotechnology, Santa Cruz, CA), apoA1 (Cell Signaling Technology, Danvers, MA), and PEDF (R&D Biosystems, Minneapolis, MN). Blots were washed, incubated with appropriate secondary horseradish peroxidase-conjugated antibodies and developed with electrochemiluminescent Western blotting detection reagents (GE Healthcare, UK).
HDL-bound SAA and SP-B were quantified by an ELISA developed by our laboratory. Binding of HDL directly from apoB-depleted serum samples onto a 96-well plate was attained using a coating antibody against HDL (Sigma-Aldrich) at 1 mg/ml. HDL samples (10 mg/ml) with high and low amounts of SAA and SP-B were used as positive and negative controls. Samples were added in triplicates at 1:50 dilution for 1.5 hours, followed by incubation with primary antibodies against SAA and SP-B (Santa Cruz Biotechnology) for 1 hour and appropriate secondary biotin-conjugated antibodies (Southern Biotech, Birmingham, AL) for another hour. After adding streptavidin-peroxidase (Roche, Basel, Switzerland) to the plates for 30 minutes, protein levels were detected using tetramethylbenzidine substrate (Sigma-Aldrich) and measuring OD at 450 nm. Data are expressed normalized to the ratio of positive to negative control.
Statistical Analyses
One-way ANOVA was used to assess differences between all groups. Differences in HDL parameters between two groups were calculated using the Mann-Whitney U test and the t test. Data yielding a twotailed P value ,0.05 were considered to indicate statistical significance. Statistical analysis was performed using GraphPad Prism software (GraphPad 6 software).
